Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia NDA – FDA Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s request for additional primate studies to assess potential skin toxicity stemmed from findings with other agents of the same class, agency review documents show.
Advertisement

Related Content

Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients
Merck Builds On Januvia Momentum With Two Supplementary Claims
OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Bristol Aims To Be First To Market With Novel Diabetes Drug Class
Merck Aims To Duplicate Januvia Launch Success In 2007
Bristol Eyes 2008 NDA For DPP-4 Inhibitor Saxagliptin
Merck’s Januvia/Metformin Combo To Be Branded Janumet
Galvus Review Delayed For Safety Analysis Of Primate Skin Data
Galvus Review Delayed For Safety Analysis Of Primate Skin Data
OSI Seeks Partner For DPP-4 Inhibitor Paused At Phase III Gate

Topics

Advertisement
UsernamePublicRestriction

Register

PS065057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel